A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Phase 3 Completed 460 enrolled Bayer

RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease (PID)

Timeline

Start: 2007-01
Primary completion: 2008-05
Completion: 2008-05

Publications

Results Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG. 2010 Nov;117(12):1475-84. doi: 10.1111/j.1471-0528.2010.02687.x. Epub 2010 Aug 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Levofloxacin	Small molecule	500 mg	Oral
Comparator	Metronidazole	Small molecule	500 mg	Oral
Subject	Moxifloxacin	Small molecule	400 mg	Oral

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Summary

Timeline

Publications

Drugs

Indications